Post by onefreetrajectory on May 5, 2021 16:07:08 GMT
Oxford, UK, and Pasadena, Calif. – March 19, 2021 – Rockley Photonics, Ltd. (“the Company” or “Rockley”), a leading global supplier of integrated silicon photonic chips and modules across multiple markets, today announced that it has entered into a definitive agreement to combine with SC Health Corp. (“SC Health”) (NYSE: SCPE), a publicly traded special purpose acquisition company. The transaction will result in Rockley becoming a publicly traded company on the NYSE under the symbol RKLY and values the Company at a pro forma enterprise value of $1.2 billion.
Transforming healthcare through revolutionary “clinic-on-the-wrist” monitoring technology
Transforming healthcare through revolutionary “clinic-on-the-wrist” monitoring technology
The transaction will accelerate the commercial launch of Rockley’s unique sensing platform, which is positioned to revolutionize consumer health and wellness by enabling continuous, non-invasive monitoring of multi-modal biomarkers such as lactate, glucose, hydration, blood pressure, and core body temperature.
Built on its highly disruptive silicon photonics platform, Rockley’s “clinic-on-the-wrist” technology is significantly more accurate than LED sensors commonly used today in wearables such as smart watches and fitness bands and allows for continuous monitoring of key vitals in a way that was previously possible only with clinical machines. By bringing laboratory precision diagnostics to wearables, Rockley will enable consumers to detect diseases earlier, better manage nutrition, and focus on preventive healthcare so they can live better and healthier lives.
Rockley is working closely and deeply with some of the world’s largest consumer electronics and wearables companies to provide them with a full-stack solution, including co-packaged hardware devices, biosensing algorithms, firmware, and data analytics to enable these customers to provide meaningful and actionable insights to their users.
Beyond consumer electronics, Rockley is partnering with clinicians and MedTech companies to expand
the application of its revolutionary monitoring platform to medical devices to improve disease detection
and prevention.
Beyond consumer electronics, Rockley is partnering with clinicians and MedTech companies to expand
the application of its revolutionary monitoring platform to medical devices to improve disease detection
and prevention.
Rockley’s platform supports cost-effective, high-volume manufacturing. Its manufacturing ecosystem, with capacity reserved, and proprietary process flows will enable rapid scale-up for volume production of its highly integrated optical/electronic devices.
Rockley has also applied its integrated photonics technology to deliver best-in-class chipsets for high- speed data communications and machine vision applications, including LiDAR. Its technology is protected by over 120 patents and the Company has raised $390 million in funding from over seven years of product development from non-recurring engineering, investors, government grants, subsidies and a range of world-class health-tech and technology VCs, strategic investors, and financial institutions.
rockleyphotonics.com/investors/
www.macrumors.com/2021/05/03/apple-watch-blood-pressure-glucose-alcohol/
rockleyphotonics.com/investors/
www.macrumors.com/2021/05/03/apple-watch-blood-pressure-glucose-alcohol/
Apple has been revealed to be the largest customer of the British electronics start-up Rockley Photonics, The Telegraph reports.
Rockley Photonics has developed non-invasive optical sensors for detecting multiple blood-related health metrics, including blood pressure, blood glucose, and blood alcohol levels, many of which are only normally detectable with more invasive dedicated medical equipment. Rockley's sensors beam infrared light through a user's skin, much like the existing sensors on the back of the Apple Watch for detecting heart rate and blood oxygen levels.
Rockley's disclosure that its biggest client is Apple came about as the company prepares to go public in New York. The company's filings said that Apple accounted for the majority of its revenue over the last two years and that it has an ongoing "supply and development agreement" with the company, under which it expects to continue to heavily rely on Apple for most of its revenue.
Given the growth of Rockley Photonics and the scale of Apple's partnership with the company, it seems to be virtually inevitable that the company's health sensor technology will be coming to the Apple Watch sooner rather than later.
Rockley Photonics has developed non-invasive optical sensors for detecting multiple blood-related health metrics, including blood pressure, blood glucose, and blood alcohol levels, many of which are only normally detectable with more invasive dedicated medical equipment. Rockley's sensors beam infrared light through a user's skin, much like the existing sensors on the back of the Apple Watch for detecting heart rate and blood oxygen levels.
Rockley's disclosure that its biggest client is Apple came about as the company prepares to go public in New York. The company's filings said that Apple accounted for the majority of its revenue over the last two years and that it has an ongoing "supply and development agreement" with the company, under which it expects to continue to heavily rely on Apple for most of its revenue.
Given the growth of Rockley Photonics and the scale of Apple's partnership with the company, it seems to be virtually inevitable that the company's health sensor technology will be coming to the Apple Watch sooner rather than later.